Shares of Latin America's largest petrochemicals producer slid 7.1% to $7.08 on June 25, extending a punishing multi-day selloff as investors digested a toxic cocktail: ballooning losses, a balance sheet in negative territory, and a fresh regulatory probe that has amplified uncertainty around the company's future.

  • Losses Keep Piling Up, and the Balance Sheet Has Turned Upside Down. Braskem reported a BRL 11.32 billion loss for 2024. Things got worse: for 2025, Braskem recorded a loss of R$9.88 billion, taking accumulated losses to R$23.9 billion and shareholders' equity to negative R$16.1 billion. Negative equity means the company's debts now exceed everything it owns — a red flag that typically locks companies out of capital markets and forces restructuring. The 2025 financial statements carry a going concern footnote due to increasing pressure on liquidity, signaling materially heightened solvency risk. For shareholders, this means dividend payments are off the table indefinitely, and the stock effectively trades on recovery hopes alone.

  • A Geological Disaster Still Haunts the Books. Braskem has allocated R$14.4 billion (~$2.9 billion) to address ground subsidence from 40 years of salt mining in Maceió. Just two days ago, Braskem responded to Brazil's securities regulator CVM about a Federal Police investigation into the subsidence.

The Alagoas Public Defender's Office has requested an additional BRL 4 billion in compensation — a liability that could swell provisions further and deepen the equity hole.

  • The Tanure Takeover Bid Raises More Questions Than Answers. Nelson Tanure presented a proposal to acquire 50.1% of voting shares currently held by Novonor (formerly Odebrecht). But the proposal does not include a mandatory tender offer for minority shareholders, nor tag-along rights — protections that guarantee small investors get the same price as the controlling shareholder. Negotiations persist despite the end of the exclusivity window. Without Petrobras's blessing — it holds 47% of voting shares and supplies key raw materials — the deal may never close.

  • Operating Gains Can't Outrun Structural Debt. Braskem posted a 46% increase in EBITDA for 2024, reaching $1.1 billion. Yet financial leverage excluding its Mexico joint venture reached 14.38 times EBITDA — an extreme ratio for any industrial company. In 2025, EBITDA dropped another 49%, and restructuring is now underway. Until spreads recover or a credible new owner injects capital, the stock remains a speculation on survival, not on growth.